Stiripentol compared with placebo for focal refractory epilepsy

Patient or population: people with focal refractory epilepsy

Settings: community

Intervention: stiripentol

Comparison: placebo

≥ 50% seizure reduction

RR 1.51 (0.81 to 2.82)

32
(1)

⊕⊕⊖⊖

low^a,b

Seizure freedom

RR 1.18 (0.31 to 4.43)

32
(1)

⊕⊕⊖⊖

low^a,b

≥ 1 adverse effect

RR 2.65 (1.08 to 6.47)

32
(1)

⊕⊕⊖⊖
low^a,b

Neurological adverse effects

RR 2.65 (0.88 to 8.01)

32
(1)

⊕⊕⊖⊖
low^a,b

Gastrointestinal adverse effects

RR 11.56 (0.71 to 189.36)

32
(1)

⊕⊕⊖⊖
low^a,b

Dropouts

RR 0.66 (0.30 to 1.47)

32
(1)

⊕⊕⊖⊖
low^a,b

* Quality of life was not assessed in this study.

**The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) and is calculated according to the following formula: corresponding intervention risk, per 1000 = 1000 X ACR X RR.
ACR: assumed control risk; CI: confidence interval; RR: risk ratio

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.
Low quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different .
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.